Skip to main content

Mintz Advises Biolog-id in SPAC Transaction

Boston, MA – Mintz is serving as legal advisor to Biolog-id, a digital health solution provider focusing on value-chain optimization, in its agreement to become a publicly-traded company via a business combination with Genesis Growth Tech Acquisition Corp. (Nasdaq: GGAA) (“GGAA” or “Genesis”), a special purpose acquisition company (SPAC), with an implied equity value of $312 million for Biolog-id. After the transaction closes, which is expected to take place in the first quarter of 2023, the combined company is expected to list on the Nasdaq under the ticker symbol “BGID.”

Based in Bernay, France, Biolog-id designs, deploys and supports integrated traceability solutions, including hardware, real-time data collection, visualization and data analysis, based on radio frequency identification, or RFID, technology, to handle sensitive health products. Biolog-id uses high frequency RFID technology to transform lifesaving and sensitive therapeutic products into connected devices.

“The Mintz team worked seven days a week across time zones and guided the Biolog-id team through the complexities of this transaction to where we now have a deal signed, helping to further our vision of improved patient care worldwide,” said Troy Hilsenroth, CEO of Biolog-id. “Our team at Mintz helped us navigate through the complexities of our transaction and brought to bear their expertise in SPAC transactions and cross-border M&A. We value their advice and counsel and their pragmatic and business-minded approach to deal making.”

The Mintz team advising Biolog-id is led by Member and Chair of the firm’s Israel Practice Ran Zioni and Member Jeffrey Schultz, and included, among other Mintz attorneys and professionals, Member Stephen Osborn and Associates Jason Miller and Wills Klein.

Mintz is a pioneering firm, recognized as an early adopter and at the forefront of SPAC transactions since the early 2000s. Having handled the first-ever New York Stock Exchange SPAC transaction, the firm’s interdisciplinary team draws from decades of experience guiding clients in a broad spectrum of industries through the intricacies of SPAC financings. Notably, the firm has handled over 60 SPAC and reverse merger transactions and worked on several recent SPACs for multi-billion-dollar value companies. 

Mintz’s Mergers & Acquisitions Practice includes an interdisciplinary group of more than 100 professionals from many areas of specialization, including corporate, tax, intellectual property, employee benefits, environmental, regulatory, real estate, antitrust, and others. The firm’s portfolio of successful deals includes transactions of virtually every size and type, from large public-to-public mergers to sales of private venture-backed businesses to negotiated and contested transactions and domestic, international, and cross-border transactions. 

Mintz’s Securities and Capital Markets attorneys represent 50+ domestic and international public companies and help them navigate the challenges of life as a public company. Our experience includes representing our clients in hundreds of initial public offerings (IPOs) and follow-on offerings in the public equity market, assisting our clients in navigating the complex disclosure requirements involved in public company reporting, Sarbanes-Oxley and Dodd-Frank Act compliance, corporate governance, shareholder relations, equity compensation planning, and board and committee-level counsel and strategic advice.

For more information about Mintz, please visit